Hitting the Bullseye in NSCLC:
Updates on EGFR-Targeting Therapies

ezgif.com-webp-to-png

This series is provided by Global Education Group. (ACCME Credit)

This series is jointly provided by Global Education Group and Integritas Communications. (AANP & ACPE Credit)

This series is supported by an educational grant from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Overall Program Description

Lung cancer is the second most common cancer in both men and women and is the leading cause of cancer-related deaths. The majority of lung cancer cases are categorized as NSCLC, which has a low overall 5-year survival rate, especially when it is diagnosed at advanced, unresectable stages. Recent advances in the treatment landscape have yielded promising improvements in progression-free survival and overall survival; however, outcomes are dependent on numerous factors, including the evaluation of mutational status and prompt implementation of targeted therapeutic strategies. This 4-part CME Snapshot activity has been designed to educate and promote critical thinking through a discussion-based format, with elements of 3D animation. Multidisciplinary expert faculty discuss the appropriate molecular testing techniques to evaluate mutational status and provide practical recommendations for individualized treatment strategies in unresectable EGFR+ NSCLC based on their clinical experience and the latest published clinical evidence.

Target Audience

The educational design of this activity addresses the needs of oncology, interventional radiology, oncology pharmacy, and pathology clinicians (MDs, PAs, NPs, and nurses) involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Activities

Module 1

Molecular Classification of NSCLC

Faculty Heather Wakelee, MD, FASCO; Gerald Berry, MD

Credits Maximum of 0.25 AMA PRA Category 1 Credit(s)™, 0.25 AANP contact hour(s), and 0.25 CPE

Expiration2024-09-29

Module 2

An Overview of EGFR-Targeting Agents

Faculty Heather Wakelee, MD, FASCO; Stefanie Houseknecht, PharmD, BCOP

Credits Maximum of 0.25 AMA PRA Category 1 Credit(s)™, 0.25 AANP contact hour(s), and 0.25 CPE

Expiration2024-09-29

Module 3

Treatment Approaches for EGFR + NSCLC

Faculty Heather Wakelee, MD, FASCO; Anjali Sibley MD, MPH

Credits Maximum of 0.25 AMA PRA Category 1 Credit(s)™, 0.25 AANP contact hour(s), and 0.25 CPE

Expiration2024-09-29

Module 4

Overcoming Treatment Challenges in EGFR + NSCLC

Faculty Heather Wakelee, MD, FASCO; Anjali Sibley MD, MPH

Credits Maximum of 0.25 AMA PRA Category 1 Credit(s)™, 0.25 AANP contact hour(s), and 0.25 CPE

Expiration2024-09-29